Amgen's Imdelltra plus AstraZeneca's Imfinzi improves overall survival in extensive-stage small cell lung cancer in Phase 3.
Amgen reported a key clinical win for its T cell engager platform, finding that Imdelltra combined with a checkpoint inhibitor helped patients with advanced lung …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival win…
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new phase 3…
A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of…
Approval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDYLLTRA Compared to Chemotherapy
No estudo clínico, foram combinados o Imfinzi, da AstraZeneca, com o Imdelltra, da Amgen
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval…
